Melanoma, RAC1 mutation, mutational analysis, systemic treatment, immune checkpoint inhi-bition, targeted therapy
immune checkpoint inhibition, hypercalcemia of malignancy, penile squamous cell carcinoma, hypercalcemic psychosyndrome, immune-mediated hypercalcemia
melanoma, targeted therapy, BRAF and MEK inhibitors, Anticoagulation, Direct oral anticoagulants (DOACs), Factor Xa inhibitors, Progression-free survival (PFS), Overall survival (OS), Platelet aggregation inhibition, Venous thromboembolism (VTE), Immunothrombosis
Melanoma, sex, Targeted therapy, immune checkpoint inhibition therapy, Survival